Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Gynecologic Oncology Group
With
Fudan University
Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University
Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Group 1:
Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.
Complete data on first-line treatment and maintenance therapy.
Availability of follow-up data.
Group 2:
Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.
Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.
Complete data on second-line treatment and maintenance therapy.
